RxDoctor Payments Data

Randall Piette, MD

Internal Medicine · Sun City, AZNPI 1154314243

Payments from drug & device makers

$11,022in general payments, 2019–2025

Across 575 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$971
  • GSK$837
  • AbbVie$690
  • Pfizer$671
  • Boehringer Ingelheim$669
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$11,022100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,022 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$429,351
Medicare patients
752
Services billed
6,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin239$310,469
EliquisApixaban128$179,468
JanuviaSitagliptin Phosphate90$109,721
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$92,306
XareltoRivaroxaban44$61,493
GemtesaVibegron39$50,283
OzempicSemaglutide27$48,613
TradjentaLinagliptin26$37,169
RybelsusSemaglutide13$35,547
MyrbetriqMirabegron24$29,603
FarxigaDapagliflozin Propanediol15$21,652
Breo ElliptaFluticasone/Vilanterol23$16,205
VascepaIcosapent Ethyl15$15,750
Janumet XrSitagliptin Phos/Metformin Hcl11$15,395
Levothyroxine Sodium1,301$14,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$669$347,638265 claims
PfizerEliquis$671$179,468128 claims
MerckJanuvia, Janumet Xr$189$125,116101 claims
GSKTrelegy Ellipta, Breo Ellipta$837$108,51191 claims
Novo NordiskOzempic, Rybelsus$397$84,16040 claims
Johnson & JohnsonXarelto$163$61,49344 claims
Sumitomo Pharma America, Inc.Gemtesa$435$50,28339 claims
Astellas Pharma US IncMyrbetriq$359$29,60324 claims
AstraZenecaFarxiga, Symbicort$971$28,59029 claims
AbbVieSynthroid$690$6,038124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Sun City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →